Skip to Main Content

Hello, everyone, and welcome to another busy day, although one could not tell from the unusually quiet Pharmalot campus, where the short person and official mascots are all sleeping in. We, however, are wide awake, thanks to multiple cups of stimulation — we are back to Hazelnut Creme, for those who track this sort of thing. On that note, time to get cracking. Here are some tidbits for you to peruse. Hope your day goes well and you conquer the world …

A Novartis anti-inflammatory drug cut cardiovascular risk for heart attack survivors in a notable trial, which could change ideas about treatment, Reuters reports. The drug, which is called Ilaris, is already approved for rare autoimmune conditions and was also found to reduce further heart attacks or strokes, when used with current therapies. Industry analysts said the findings were unexpected.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!